An observational study in AORTIC VALVE DISEASES and Bicuspid Aortic Valve (BAV), sponsored by Xijing Hospital. Recruiting at 4 sites in China. Open to participants aged 50 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-05-27.
Sponsored by Xijing Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Aortic Valve Disease with a site in China — 16 open to participants now, 18 under way, none of them phase 3. Aortic Valve Disease · China.
Among the 27 studies in Aortic Valve Disease with a site in China, this one is the 9th largest by planned enrollment of the 13 observational ones that give a count, is one of 4 that started in 2025, is one of 13 observational ones, reaches primary completion later than 13 of the 17 other live ones, and was the 20th registered.
235 studies on the registry are indexed under Aortic Valve Disease; 71 are open to participants now.
Browse Aortic Valve Disease studies →16 of the 27 studies in Aortic Valve Disease with a site in China are open now. Recruiting first, the newest first:
West China Hospital · Sites in China
Ages 35–80
Mitrassist Lifesciences Limited Co., Ltd. · Sites in China
Ages 50+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18+
Ruijin Hospital · Sites in China
Ages 60+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 46 Aortic Valve Disease studies recruiting now, 34 (74%) set no upper age limit and 5 (11%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.
This study: 50 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 4 started in 2025.
This study's planned enrollment of 450 is above the median of 200 across 107 observational studies indexed under Aortic Valve Disease.
Median enrollment 98 across the 14 interventional studies, 1,000 across the 13 observational. Of the 4 that completed or were terminated, 1 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 27 have an industry lead sponsor. The 10 most frequent:
Xijing Hospital is the lead sponsor of 475 studies on the registry; 158 are open to participants now.
Xijing Hospital has 3 studies filed under Aortic Valve Disease — fewer than ten, so there is no comparison to draw.
2 of the studies in Aortic Valve Disease with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04864145Nanjing First Hospital, Nanjing Medical UniversityTranscatheter Self-expandable Valve Implantation for the Treatment of Severe Native Aortic Regurgitation | 2026-12-30 |
| NCT06818084Ruijin HospitalTRanscAtheter TreatMent of PurE Aortic Regurgitation With VitaFlow Liberty System | 2027-11-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 27 studies in Aortic Valve Disease with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Safety, effectiveness and durability of Sapien 3 transcatheter aortic valve replacement in young aortic valve stenosis patients from China:A multi-center, retrospective and prospective, single arm, observational study
Transcatheter aortic valve replacement (TAVR) has revolutionized the treatment of patients with severe aortic stenosis (AS). Currently TAVR indication has expanded to intermediate and low-risk patients from inoperable or high-risk patients, through a rigorous series of clinical trials comparing TAVR with surgical aortic valve replacement (SAVR).
Despite 2020 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines recommended SAVR for patients with symptomatic severe AS aged \<65 years, the previous data from United States nationwide Vizient Clinical Data Base and Northern New England Cardiovascular Disease Group Consortium (NNECDSG) registry demonstrated dramatic growth in TAVR utilization in younger patients aged \<65 years from 2015 to 2021/2022, which is possibly driven by increased TAVR utilization in low surgical risk patients.
However, TAVR has never been systematically tested in young (\<65 years old), low-risk patients, with many unanswered questions, especially the safety and effectiveness of TAVR in patients with bicuspid aortic valves and the durability of transcatheter heart valves. Furthermore, we noticed that the patients between 65 years old and 70 years old accounted for 23.3% of all the TAVR patients and this patient subgroup were underrepresented in the previous study, which makes it necessary to also explore the interested endpoints in this subgroup.
The aim of this study is to establish the safety and efficacy of Sapien 3 TAVR in young (50\~70 years old) Chinese patients with severe symptomatic AS, including Type-1 bicuspid population and to explore the durability performance of Sapien 3 in this cohort.
Young (50\~70 years old) Chinese patients with severe symptomatic AS, including Type-1 bicuspid population
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects must meet ALL of the following inclusion criteria to be eligible for participation:
Severe AS, defined as follows:
a) For symptomatic patients: i) Aortic valve area ≤1.0 cm2 (or aortic valve area index of ≤0.6 cm2/m2), OR mean gradient ≥40 mm Hg, OR Maximal aortic valve velocity ≥4.0 m/sec by transthoracic echocardiography at rest b) For asymptomatic patients: i) Very severe AS with an aortic valve area of ≤1.0 cm2 (or aortic valve area index of ≤0.6 cm2/m2), AND maximal aortic velocity ≥5.0 m/sec, or mean gradient ≥60 mm Hg by transthoracic echocardiography at rest, OR ii) Aortic valve area of ≤1.0 cm2 (or aortic valve area index of ≤0.6 cm2/m2), AND a mean gradient ≥40 mm Hg or maximal aortic valve velocity ≥4.0 m/sec by transthoracic echocardiography at rest, AND an exercise tolerance test that demonstrates a limited exercise capacity, abnormal BP response, or arrhythmia OR iii) Aortic valve area of ≤1.0 cm2 (or aortic valve area index of ≤0.6 cm2/m2), AND mean gradient ≥40 mmHg, or maximal aortic valve velocity ≥4.0 m/sec by transthoracic echocardiography at rest, AND a \<50%.
Exclusion Criteria:
Subjects are NOT eligible for participation if they meet ANY of the following exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Procedure: TAVR
Procedure: Transcatheter Aortic Valve Replacement (TAVR)
Procedure: TAVR
Procedure: Transcatheter Aortic Valve Replacement (TAVR)
TAVR procedure was performed according to standard clinical practice. Successful vascular access, delivery and deployment of the device and successful retrieval of the delivery system will be attempted. Vascular access site will be through transfemoral on the basis of pre-procedural evaluation of access site vessel. The procedure will be performed under local or general anesthesia and per clinical practice standard.
All-cause mortality
The primary end point is the 5 year all-cause mortality
Time frame: At 5 years
The composite of all-cause mortality, stroke and rehospitalization
The composite of all-cause mortality, stroke, rehospitalization (procedure, valve and heart failure related) at 30 days, 1, 3, 5 years
Time frame: At 30 days, 1, 3, 5 years
The composite of device success
The composite of device success at 30 days comprising the following: freedom from mortality, successful access, delivery of the device, and retrieval of the delivery system, correct positioning of a single prosthetic heart valve into the proper anatomical location, freedom from surgery or intervention related to the device or to a major vascular or access-related, or cardiac structural complication, intended performance of the valve (mean gradient \<20 mmHg, peak velocity \<3 m/s, Doppler velocity index ≥0.25, and less than moderate aortic regurgitation), according to the VARC-3 definition
Time frame: At 30 days
The durability performance of Sapien 3
The durability performance of Sapien 3 at 1, 3, 5 years: bioprosthetic valve dysfunction (BVD, including SVD, non-SVD, endocarditis and thrombosis), moderate or severe hemodynamic valve deterioration (HVD), bioprosthetic valve failure (BVF) according to the VARC-3 definition, EOA/mean gradient (MG) change over follow up
Time frame: At 1, 3, 5 years
Annular rupture
The incidence of annular rupture
Time frame: At 1 day of discharge
Paravalvular leakage
The incidence of paravalvular leakage
Time frame: At 1 day of discharge, 30 days, 1, 3, 5 years
Technical success
Technical success (at exit from procedure room): * freedom from mortality * successful access, delivery of the device, and retrieval of the delivery system * correct positioning of a single prosthetic heart valve into the proper anatomical location * freedom from surgery or intervention related to the device or to a major vascular or access-related, or cardiac structural complication
Time frame: At exit from procedure room
Procedural success
Procedural success at 30 days defined as meeting all of the following: * Device success * No device or procedure related SAE's as follows: 1. Life-threatening bleed (BARC 3b or greater) 2. Major vascular or cardiac structural complications requiring unplanned reintervention or surgery 3. Stage 2 or 3 AKI (includes new dialysis) 4. MI or need for PCI/CABG 5. Severe heart failure or hypotension requiring IV inotrope \>12 hours, ultrafiltration or mechanical circulatory support 6. Prolonged intubation \> 48 hours 7. Need for a permanent pacemaker implant or continuous, new onset atrial fibrillation
Time frame: At 30 days
Mortality (all cause & cardiovascular)
The incidence of mortality (all cause \& cardiovascular)
Time frame: At 30 days, 1, 3, 5 years
Stroke (disabling and nondisabling)
The incidence of stroke (disabling and nondisabling)
Time frame: At 30 days, 1, 3, 5 years
Rehospitalization (procedure, valve and heart failure related)
The incidence of rehospitalization (procedure, valve and heart failure related)
Time frame: At 30 days, 1, 3, 5 years
Major vascular complication
The incidence of major vascular complication
Time frame: At 30 days, 1, 3, 5 years
Major or life-threatening bleeding
The incidence of major or life-threatening bleeding
Time frame: At 30 days, 1, 3, 5 years
Myocardial infarction
The incidence of myocardial infarction
Time frame: At 30 days, 1, 3, 5 years
Acute kidney injury stage 2 or 3
The incidence of acute kidney injury stage 2 or 3
Time frame: At 30 days, 1, 3, 5 years
Need for a permanent pacemaker
The incidence of permanent pacemaker implantation
Time frame: At 30 days, 1, 3, 5 years
New onset atrial fibrillation
The incidence of new onset atrial fibrillation
Time frame: At 30 days, 1, 3, 5 years
Valve endocarditis
The incidence of valve endocarditis
Time frame: At 30 days, 1, 3, 5 years
Valve thrombosis
The incidence of valve thrombosis
Time frame: At 30 days, 1, 3, 5 years
New York Heart Association class
The changes in New York Heart Association class
Time frame: At 30 days, 1, 3, 5 years
Patient-prosthesis mismatch
The incidence of patient-prosthesis mismatch
Time frame: At 30 days, 1, 3, 5 years
Health status as evaluated by Quality of Life questionnaires - KCCQ
The changes in Health status as evaluated by Quality of Life questionnaires - KCCQ
Time frame: At baseline, 30 days, 1, 3, 5 years
Plan to share: No — Individual participant data (IPD) would not be shared, according to local authority data privacy policy.
Started Apr 2025 (actual). Primary completion is estimated for Jun 2031, 74 months after the start.
Of 47 non-industry observational studies under Aortic Valve Disease, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 147. This study's planned 74 months is above that.
Counting every sponsor, half of 56 studies reached it within 49 months; a quarter within 23 and three quarters within 97.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.